Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Expert Answers to Questions on Contemporary Management of Hemophilia A

In this podcast episode, listen to Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, as they answer questions from a clinician audience on new and established approaches for managing hemophilia A in pediatric and adult patients.
Michael Callaghan, MD
Miguel A. Escobar, MD
person default
Rebecca Kruse-Jarres, MD, MPH
Released: February 4, 2021

In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including:

  • Maintaining long-term musculoskeletal health
  • Identifying patients most likely to benefit from pharmacokinetics-guided prophylaxis
  • Managing combination therapies in older patients with comorbidities
  • Youngest age at which patients can be considered for emicizumab
  • Development of resistance to emicizumab
  • Switching recombinant factor therapies
  • Using bypassing agents with emicizumab for breakthrough bleeds in patients with inhibitors
  • Potential clinical role of extending FVIII half-life with BIVV001
  • Considerations when dosing emicizumab monthly


Michael Callaghan, MD
Associate Professor
Department of Hematology
Wayne State University
Division of Hematology/Oncology
Children’s Hospital of Michigan
Detroit, Michigan

Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Rebecca Kruse-Jarres, MD, MPH
Department of Medicine
University of Washington
Executive/Medical Director
Washington Institute for Coagulation
Seattle, Washington


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Genentech, a member of the Roche Group
Sanofi Genzyme Corporation
Takeda Pharmaceutical Company Ltd

Related Content

Gain expert pharmacist insight on the management of hemophilia A with factor and nonfactor replacement therapies

person default Justin Arnall, PharmD, BCOP person default Kayla Douglas, PharmD Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 24, 2022 Expired: May 23, 2023

Downloadable resource from Clinical Care Options (CCO) to share with patients that covers the basics of hemophilia A and differences between available prophylaxis therapies

Glaivy Batsuli, MD Released: May 9, 2022

From Clinical Care Options (CCO), video webinar on recent advances in management of acute and chronic GVHD for physicians, nurses, and pharmacists

Corey Cutler, MD, MPH, FRCPC David Miklos, MD, PhD Robert Zeiser, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: May 4, 2022 Expired: May 3, 2023

GVHD experts address key questions about the treatment of patients with graft versus host disease in this commentary from Clinical Care Options (CCO)

Corey Cutler, MD, MPH, FRCPC Released: May 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings